
    
      Patients will be offered to participated in the study after the first 6 weeks of the
      nationally recommended TB treatment. All the enrolled patients will be switched to rifabutin
      and randomized, two weeks later, to one of the three study ARV regimens. The RBT doses will
      be then adapted to the allocated ARV regimen according to a cross over scheme. Three full
      pharmacokinetics profile will be performed at different time point : before initiation of
      ARV, after one month of the first RFB dosage and one month after the second RFB dosage.
    
  